CLOS
MDGL icon

Compagnie Lombard Odier SCmA’s Madrigal Pharmaceuticals MDGL Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24
Closed -$12.3K – 478
2026
Q1 		$12.6K Hold
24
– – ﹤0.01% 381
2025
Q4 		$14K Sell
24
-80
-77% -$40.9K ﹤0.01% 382
2025
Q3 		$47.7K Hold
104
– – ﹤0.01% 347
2025
Q2 		$31.5K Hold
104
– – ﹤0.01% 349
2025
Q1 		$34.4K Hold
104
– – ﹤0.01% 378
2024
Q4 		$32.1K Hold
104
– – ﹤0.01% 362
2024
Q3 		$22.1K Hold
104
– – ﹤0.01% 390
2024
Q2 		$29.1K Buy
104
+24
+30% +$5.71K ﹤0.01% 364
2024
Q1 		$21.4K Buy
+80
New +$18.9K ﹤0.01% 402

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Compagnie Lombard Odier SCmA's MDGL Position: Q2 2026 in Review

Compagnie Lombard Odier SCmA sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 24 shares — an estimated $12.3K sold.

Compagnie Lombard Odier SCmA first reported a position in MDGL in Q1 2024 and held it in 9 quarters. The position peaked at $47.7K in Q3 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Compagnie Lombard Odier SCmA reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 24 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $12.3K.
  • Compagnie Lombard Odier SCmA first reported a position in Madrigal Pharmaceuticals in Q1 2024 and held it in 9 quarters.
  • Compagnie Lombard Odier SCmA's Madrigal Pharmaceuticals position peaked at $47.7K in Q3 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.